Literature DB >> 17984097

The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

Christine Beeton1, Brian J Smith, Jennifer K Sabo, George Crossley, Daniel Nugent, Ilya Khaytin, Victor Chi, K George Chandy, Michael W Pennington, Raymond S Norton.   

Abstract

The polypeptide toxin ShK is a potent blocker of Kv1.3 potassium channels, which are crucial in the activation of human effector memory T cells (T(EM)); selective blockers constitute valuable therapeutic leads for the treatment of autoimmune diseases mediated by T(EM) cells, such as multiple sclerosis, rheumatoid arthritis, and type-1 diabetes. The critical motif on the toxin for potassium channel blockade consists of neighboring lysine and tyrosine residues. Because this motif is sufficient for activity, an ShK analogue was designed based on D-amino acids. D-allo-ShK has a structure essentially identical with that of ShK and is resistant to proteolysis. It blocked Kv1.3 with K(d) 36 nm (2,800-fold lower affinity than ShK), was 2-fold selective for Kv1.3 over Kv1.1, and was inactive against other K(+) channels tested. D-allo-ShK inhibited human T(EM) cell proliferation at 100-fold higher concentration than ShK. Its circulating half-life was only slightly longer than that of ShK, implying that renal clearance is the major determinant of its plasma levels. D-allo-ShK did not bind to the closed state of the channel, unlike ShK. Models of D-allo-ShK bound to Kv1.3 show that it can block the pore as effectively as ShK but makes different interactions with the vestibule, some of which are less favorable than for native ShK. The finding that an all-D analogue of a polypeptide toxin retains biological activity and selectivity is highly unusual. Being resistant to proteolysis and nonantigenic, this analogue should be useful in K(+) channel studies; all-d analogues with improved Kv1.3 potency and specificity may have therapeutic advantages.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984097     DOI: 10.1074/jbc.M706008200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  KCa1.1 potassium channels regulate key proinflammatory and invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  Xueyou Hu; Teresina Laragione; Liang Sun; Shyny Koshy; Karlie R Jones; Iskander I Ismailov; Patricia Yotnda; Frank T Horrigan; Pércio S Gulko; Christine Beeton
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

2.  Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Authors:  M W Pennington; C Beeton; C A Galea; B J Smith; V Chi; K P Monaghan; A Garcia; S Rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Journal:  Mol Pharmacol       Date:  2009-01-02       Impact factor: 4.436

3.  Inversion of the Side-Chain Stereochemistry of Indvidual Thr or Ile Residues in a Protein Molecule: Impact on the Folding, Stability, and Structure of the ShK Toxin.

Authors:  Bobo Dang; Rong Shen; Tomoya Kubota; Kalyaneswar Mandal; Francisco Bezanilla; Benoit Roux; Stephen B H Kent
Journal:  Angew Chem Int Ed Engl       Date:  2017-02-14       Impact factor: 15.336

Review 4.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

5.  OLIG2 over-expression impairs proliferation of human Down syndrome neural progenitors.

Authors:  Jie Lu; Gewei Lian; Hui Zhou; Giuseppe Esposito; Luca Steardo; Laurent C Delli-Bovi; Jonathan L Hecht; Q Richard Lu; Volney Sheen
Journal:  Hum Mol Genet       Date:  2012-02-17       Impact factor: 6.150

Review 6.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

7.  Reinvestigation of the biological activity of d-allo-ShK protein.

Authors:  Bobo Dang; Sandeep Chhabra; Michael W Pennington; Raymond S Norton; Stephen B H Kent
Journal:  J Biol Chem       Date:  2017-06-08       Impact factor: 5.157

8.  Potassium channel modulation by a toxin domain in matrix metalloprotease 23.

Authors:  Srikant Rangaraju; Keith K Khoo; Zhi-Ping Feng; George Crossley; Daniel Nugent; Ilya Khaytin; Victor Chi; Cory Pham; Peter Calabresi; Michael W Pennington; Raymond S Norton; K George Chandy
Journal:  J Biol Chem       Date:  2009-12-04       Impact factor: 5.157

9.  A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Authors:  Michael W Pennington; M Harunur Rashid; Rajeev B Tajhya; Christine Beeton; Serdar Kuyucak; Raymond S Norton
Journal:  FEBS Lett       Date:  2012-10-09       Impact factor: 4.124

Review 10.  Integrating the discovery pipeline for novel compounds targeting ion channels.

Authors:  Grzegorz Bulaj
Journal:  Curr Opin Chem Biol       Date:  2008-08-03       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.